0001140361-20-022423.txt : 20201005 0001140361-20-022423.hdr.sgml : 20201005 20201005160536 ACCESSION NUMBER: 0001140361-20-022423 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20201003 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201005 DATE AS OF CHANGE: 20201005 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 201223584 BUSINESS ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 8-K 1 brhc10015771_8k.htm CURRENT REPORT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K

CURRENT REPORT
 
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act Of 1934
 
Date of Report (Date of earliest event reported): October 3, 2020


BRISTOL-MYERS SQUIBB COMPANY
(Exact Name of Registrant as Specified in its Charter)

Delaware
001-01136
22-0790350
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification Number)
 
430 East 29th Street, 14th Floor
New York, NY, 10016
(Address of Principal Executive Office)
 
Registrant’s telephone number, including area code: (212) 546-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☒
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 Securities registered pursuant to Section 12(b) of the Act:
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Common Stock, $0.10 Par Value
   BMY
  
New York Stock Exchange
1.000% Notes due 2025
   BMY25
  
New York Stock Exchange
1.750% Notes due 2035
   BMY35
  
New York Stock Exchange
Bristol-Myers Squibb Contingent Value Rights
   BMY RT
  
New York Stock Exchange
Celgene Contingent Value Rights
   CELG RT
  
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01
Other Events.
 
On October 3, 2020, Bristol-Myers Squibb Company, a Delaware corporation (“Bristol-Myers Squibb”), and MyoKardia, Inc., a Delaware corporation (“MyoKardia”), issued a joint press release announcing that Bristol-Myers Squibb, MyoKardia and Gotham Merger Sub, Inc., a Delaware corporation and subsidiary of Bristol-Myers Squibb (“Merger Sub”)  have signed a definitive merger agreement that provides that pursuant to the merger agreement and upon the terms and subject to the conditions thereof, Merger Sub will commence a tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share, of MyoKardia (the “Shares”) at a price of $225.00 per Share, net to the seller in cash (without interest) but subject to any required withholding taxes. A copy of the joint press release announcing the proposed transaction is filed as Exhibit 99.1 to this report and is incorporated herein by reference.
 
Additional Information and Where to Find It
 
The tender offer described in this report has not yet commenced, and this communication is neither an offer to purchase nor a solicitation of an offer to sell securities. At the time the tender offer is commenced, Bristol-Myers Squibb will cause Merger Sub to file with the U.S. Securities and Exchange Commission (“SEC”) a tender offer statement on Schedule TO. Investors and MyoKardia stockholders are strongly advised to read the tender offer statement (including an offer to purchase, letter of transmittal and related tender offer documents) and the related solicitation/recommendation statement on Schedule 14D-9 that will be filed by MyoKardia with the SEC, because they will contain important information. These documents will be available at no charge on the SEC’s website at www.sec.gov. In addition, a copy of the offer to purchase, letter of transmittal and certain other related tender offer documents (once they become available) may be obtained free of charge at www.bms.com or by directing a request to Bristol-Myers Squibb, Office of the Corporate Secretary, 430 East 29th Street, 14th Floor, New York, New York 10154-0037. A copy of the tender offer statement and the solicitation/recommendation statement will be made available to all stockholders of MyoKardia free of charge at www. MyoKardia.com or by contacting MyoKardia at ir@myokardia.com, Telephone Number 650-351-4690.
 
In addition to the offer to purchase, the related letter of transmittal and certain other offer documents, as well as the solicitation/recommendation statement, Bristol-Myers Squibb and MyoKardia file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any reports, statements or other information filed by Bristol-Myers Squibb or MyoKardia at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Bristol-Myers Squibb’s and MyoKardia’s filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.
 
Forward Looking Statements
 
This report contains “forward-looking statements” relating to the acquisition of MyoKardia by Bristol-Myers Squibb and the development and commercialization of certain biological compounds. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the acquisition will be completed, or if it is completed, that it will close within the anticipated time period or that the expected benefits of the acquisition will be realized. The actual financial impact of this transaction may differ from the expected financial impact described in this report. In addition, the compounds described in this report are subject to all the risks inherent in the drug development process, and there can be no assurance that the development of these compounds will be commercially successful. Forward-looking statements in this report should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2019, and its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

2
Item 9.01.
Financial Statements and Exhibits.
 
(d) Exhibits.

99.1
Joint Press Release of Bristol-Myers Squibb Company and MyoKardia, Inc., dated October 5, 2020.
104
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
BRISTOL-MYERS SQUIBB COMPANY
     
Dated: October 5, 2020
By:
/s/ Katherine R. Kelly
 
Name:
Katherine R. Kelly
 
Title:
Corporate Secretary

EXHIBIT INDEX

Exhibit
No.
  
Description
     
 
Joint Press Release of Bristol-Myers Squibb Company and MyoKardia, Inc., dated October 5, 2020.
104
  
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).


3
EX-99.1 2 brhc10015771_ex99-1.htm JOINT PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY AND MYOKARDIA, INC.
Exhibit 99.1

Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash

Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

 Mavacamten Will Be a Medium- and Long-Term Growth Driver Presenting a Significant Commercial Opportunity upon Approval

Promising Portfolio of Pipeline Candidates Strengthens and Extends
Bristol Myers Squibb’s Leading Cardiovascular Franchise

Expected to be Accretive to Non-GAAP Earnings Starting in 2023

NEW YORK & BRISBANE, CA, October 5, 2020 – Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire MyoKardia for $13.1 billion, or $225.00 per share in cash. The transaction was unanimously approved by both the Bristol Myers Squibb and MyoKardia Boards of Directors and is anticipated to close during the fourth quarter of 2020.

MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. Through the transaction, Bristol Myers Squibb gains mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy (“HCM”), a chronic heart disease with high morbidity and patient impact. A New Drug Application (“NDA”) for mavacamten for the treatment of symptomatic obstructive HCM – based on data from the EXPLORER-HCM study – is expected to be submitted to the U.S. Food and Drug Administration (“FDA”) in the first quarter of 2021. Bristol Myers Squibb expects to explore the full potential of mavacamten in additional indications, including non-obstructive HCM, as well as develop MyoKardia’s promising pipeline of novel compounds, including two clinical-stage therapeutics: danicamtiv (formerly MYK-491) and MYK-224.

“The acquisition of MyoKardia further strengthens our portfolio, pipeline and scientific capabilities, and is expected to add a meaningful medium- and long-term growth driver,” said Giovanni Caforio, M.D., Board Chair and Chief Executive Officer of Bristol Myers Squibb. “We are further strengthening our outstanding cardiovascular franchise through the addition of mavacamten, a promising medicine with the potential to address a significant unmet medical need in patients with cardiovascular disease. Our companies share a commitment to innovation and bold science, and our respective strengths will help us realize the value inherent in this portfolio. We have long admired MyoKardia and what they have done to revolutionize cardiovascular treatments through a precision medicine approach. We look forward to welcoming their talented team to our company.”

“MyoKardia was formed eight years ago with the aim of changing the world for people with serious cardiovascular diseases through bold and innovative science. Since then, MyoKardia’s dedicated employees have established an unparalleled pipeline of targeted therapeutics designed to change the course of disease and return the heart to normal function,” said Tassos Gianakakos, Chief Executive Officer of MyoKardia. “Bristol Myers Squibb shares our vision for transforming the treatment of cardiovascular disease. They value our team and the potential of our platform and, most importantly, share our unwavering commitment to placing patients at the center of everything we do. Together, our complementary strengths and expanded resources and reach will further accelerate the pace at which we can discover, develop and commercialize our novel medicines for the benefit of people suffering from cardiovascular disease around the world.”

Compelling Benefits

Bristol Myers Squibb expects the transaction, when complete, to:


 •
Further strengthen the company’s outlook with the addition of mavacamten, which has significant commercial potential in the lead indication, obstructive HCM, and upside in additional future indications, including non-obstructive HCM.
With the high unmet medical need in obstructive HCM, mavacamten can be a significant medium- and long-term growth driver. Mavacamten demonstrated clinically meaningful results in the pivotal Phase 3 EXPLORER-HCM trial, meeting the primary and all secondary endpoints, and showed meaningful improvements in symptoms, functional status and quality of life by reducing the obstruction of blood flow from the heart. This potential first-in-class medicine, for which an NDA is expected to be submitted to the FDA in the first quarter of 2021, may help to change the course of the disease.


 •
Accelerate the expansion of Bristol Myers Squibb’s cardiovascular portfolio.
Bristol Myers Squibb has established Eliquis® (apixaban) as the #1 oral anticoagulant globally with a best-in-class profile, driven by leading commercial execution. Mavacamten will be a fully owned asset that fits well into Bristol Myers Squibb’s existing portfolio, given the company’s broad expertise in cardiovascular disease. Through this acquisition, Bristol Myers Squibb gains MyoKardia’s critical talent and capabilities on the U.S. West Coast, which will support fully realizing the opportunity in obstructive HCM and exploring the full potential of mavacamten in additional indications. Bristol Myers Squibb will also be well positioned to advance the global development of MyoKardia’s portfolio of clinical- and early-stage pipeline candidates, while continuing to advance its existing Factor XIa inhibitor program.


 •
Deliver significant financial benefits.
The transaction is expected to add a significant growth driver during the medium- to long-term. It is expected to be minimally dilutive to Bristol Myers Squibb’s non-GAAP earnings per share (EPS) in 2021 and 2022 and accretive beginning in 2023. Bristol Myers Squibb reaffirms its existing 2021 non-GAAP EPS guidance range. There is no reliable estimable comparable GAAP measure as described below.

Transaction Terms and Financing

Under the terms of the merger agreement, a subsidiary of Bristol Myers Squibb will promptly commence a tender offer to acquire all of the outstanding shares of MyoKardia’s common stock for $225.00 per share in cash. MyoKardia’s Board of Directors unanimously recommends that MyoKardia shareholders tender their shares in the tender offer.

The transaction is subject to customary closing conditions, including the tender of a majority of the outstanding shares of MyoKardia’s common stock and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Following the successful closing of the tender offer, Bristol Myers Squibb will acquire all remaining shares of MyoKardia that are not tendered into the tender offer through a second-step merger at the same price of $225.00 per share.

Bristol Myers Squibb expects to finance the acquisition with a combination of cash and debt.

About Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is a chronic, progressive disease in which excessive contraction of the heart muscle and reduced ability of the left ventricle to fill can lead to the development of debilitating symptoms and cardiac dysfunction. HCM is estimated to affect one in every 500 people.

The most frequent cause of HCM is mutations in the heart muscle proteins of the sarcomere. In approximately two-thirds of HCM patients, the path followed by blood exiting the heart, known as the left ventricular outflow tract (LVOT), becomes obstructed by the enlarged and diseased muscle, restricting the flow of blood from the heart to the rest of the body (obstructive HCM). In other patients, the thickened heart muscle does not block the LVOT, and their disease is driven by diastolic impairment due to the enlarged and stiffened heart muscle (non-obstructive HCM). In either obstructive or non-obstructive HCM patients, exertion can result in fatigue or shortness of breath, interfering with a patient’s ability to participate in activities of daily living. HCM has also been associated with increased risks of atrial fibrillation, stroke, heart failure and sudden cardiac death.

There are currently approximately 160,000 to 200,000 people diagnosed with symptomatic obstructive HCM across the U.S. and EU, with no existing effective treatment options beyond limited symptomatic relief. Patients are typically diagnosed in their 40s or 50s and the treatment is expected to be chronic. It is estimated that only approximately 25 percent of individuals with obstructive HCM and only approximately 10 percent of individuals with non-obstructive HCM have received a diagnosis.

Conference Call

At 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time today, Bristol Myers Squibb will host a conference call and a simultaneous webcast to discuss the transaction. A live webcast of the call can be accessed at Bristol Myers Squibb’s Investors page at bms.com/investors. Please connect to the website at least 15 minutes prior to the start of the call to allow adequate time for any software download that may be required. Alternatively, please call (877) 658-9096 (U.S.) or (602) 563-8733 (international) and dial the conference ID 9697843 to access the call.

Telephone replay will be available approximately three hours after the call until 11:30 a.m. ET on October 19, 2020. To access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406 (international) and dial the conference ID 9697843. The webcast will be archived on bms.com/investors.

Advisors

Gordon Dyal & Co., LLC is serving as exclusive financial advisor to Bristol Myers Squibb, and Kirkland & Ellis LLP is serving as legal counsel. Centerview Partners LLC and Guggenheim Securities are acting as joint financial advisors to MyoKardia and Goodwin Procter LLP is serving as legal counsel.

About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

About MyoKardia
MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. The company is pioneering a precision medicine approach to its discovery and development efforts by 1) understanding the biomechanical underpinnings of disease; 2) targeting the proteins that modulate a given condition; 3) identifying patient populations with shared disease characteristics; and 4) applying learnings from research and clinical studies to inform and guide pipeline growth and product advancement. MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461); danicamtiv (formerly MYK-491) and MYK-224.

MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.

Additional Information and Where to Find It
The tender offer referred to in this document has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender offer materials that Bristol Myers Squibb and its acquisition subsidiary will file with the U.S. Securities and Exchange Commission (the “SEC”). At the time the tender offer is commenced, Bristol Myers Squibb will cause its acquisition subsidiary to file with the SEC a tender offer statement on Schedule TO and MyoKardia will file a solicitation/recommendation statement on Schedule 14D-9. INVESTORS AND MYOKARDIA STOCKHOLDERS ARE STRONGLY ADVISED TO READ THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND OTHER OFFER DOCUMENTS) AND THE RELATED SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 THAT WILL BE FILED BY MYOKARDIA WITH THE SEC BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE CONSIDERED BY MYOKARDIA’S INVESTORS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Both the tender offer statement and the solicitation/recommendation statement will be available at no charge on the SEC’s website: www.sec.gov. In addition, a copy of the offer to purchase, letter of transmittal and certain other related tender offer documents (once they become available) may be obtained free of charge at www.bms.com or by directing a request to Bristol Myers Squibb, Office of the Corporate Secretary, 430 East 29th Street, 14th Floor, New York, New York 10154-0037. A copy of the tender offer statement and the solicitation/recommendation statement will be made available to all stockholders of MyoKardia free of charge at www.myokardia.com or by contacting MyoKardia at ir@myokardia.com, telephone number 650-351-4690.

In addition to the offer to purchase, the related letter of transmittal and certain other offer documents, as well as the solicitation/recommendation statement, Bristol Myers Squibb and MyoKardia file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any reports, statements or other information filed by Bristol Myers Squibb or MyoKardia at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Bristol Myers Squibb’s and MyoKardia’s filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov. INVESTORS AND MYOKARDIA’S STOCKHOLDERS ARE ADVISED TO READ THE SCHEDULE TO AND THE SCHEDULE 14D-9, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO.

Cautionary Statement Regarding Forward Looking Statements
This report contains “forward-looking statements” relating to the acquisition of MyoKardia by Bristol Myers Squibb and the development and commercialization of certain biological compounds. Such forward-looking statements are generally identified by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar words. These statements are only predictions, and such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks are (i) that there can be no guarantee that the acquisition will be completed, or if it is completed, that it will close within the anticipated time period or that the expected benefits of the acquisition will be realized, (ii) the outcome of any legal proceedings that may be instituted against the parties and others related to the merger agreement and (iii) unanticipated difficulties or expenditures relating to the proposed transaction, the response of business partners and competitors to the announcement of the proposed transaction and/or potential difficulties in employee retention as a result of the announcement and pendency of the proposed transaction. The actual financial impact of this transaction may differ from the expected financial impact described in this report. In addition, the compounds described in this report are subject to all the risks inherent in the drug development process, and there can be no assurance that the development of these compounds will be commercially successful. Forward-looking statements in this report should be evaluated together with the many uncertainties that affect Bristol Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2019, and its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and in MyoKardia’s most recent Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent quarterly reports filed on Form 10-Q with the SEC, as well as other documents that may be filed by MyoKardia from time to time with the SEC. Neither Bristol Myers Squibb nor MyoKardia undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. The forward-looking statements made in this communication relate only to events as of the date on which the statements are made.

Use of Non-GAAP Financial Information and Financial Guidance
This release contains non-GAAP financial guidance, which is adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis. These non-GAAP items are adjusted after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. Non-GAAP information is intended to portray the results of the company’s baseline performance, supplement or enhance management, analysts and investors overall understanding of the company’s underlying financial performance and facilitate comparisons among current, past and future periods. For example, non-GAAP earnings and EPS information are indications of the company’s baseline performance before items that are considered by us to not be reflective of the company’s ongoing results. In addition, this information is among the primary indicators that we use as a basis for evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting for future periods. This information is not intended to be considered in isolation or as a substitute for net earnings or diluted EPS prepared in accordance with GAAP and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.
There is no reliable or reasonably estimable comparable GAAP measure for this non-GAAP financial guidance because we are not able to reliably predict the impact of specified items beyond 2020. As a result, reconciliation of this non-GAAP measure to the most directly comparable GAAP measure is not available without unreasonable effort. In addition, the company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on our future GAAP results.

In addition, the non-GAAP financial guidance in this release excludes the impact of any potential additional future strategic acquisitions and divestitures and any specified items that have not yet been identified and quantified. The guidance also excludes macro-economic effects due to the COVID-19 pandemic that are not yet quantifiable. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release.

Contacts

Bristol Myers Squibb

Media:
media@bms.com
609-252-3345

Investors:
Tim Power, 609-252-7509, timothy.power@bms.com
Nina Goworek, 908-673-9711, nina.goworek@bms.com

MyoKardia

Michelle Corral
Executive Director, Corporate Communications and Investor Relations
MyoKardia, Inc.
650-351-4690
ir@myokardia.com

Hannah Deresiewicz (investors)
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Julie Normart (media)
W2O
628-213-3754
jnormart@w2ogroup.com


 EX-101.SCH 3 bmy-20201003.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 bmy-20201003_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 bmy-20201003_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Amendment Flag City Area Code Entity Address, City or Town Entity Address, Country Document Period End Date Entity Incorporation, State or Country Code Entity Listings [Table] Local Phone Number Entity Address, Postal Zip Code Entity Address, State or Province Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Entity Listings [Line Items] Entity Registrant Name Entity Central Index Key Entity Tax Identification Number Document Fiscal Year Focus Document Fiscal Period Focus Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity File Number Entity Emerging Growth Company Class of Stock [Domain] Common Stock [Member] Class of Stock [Axis] 1.000% Notes due 2025 [Member] 1.750% Notes due 2035 [Member] Bristol-Myers Squibb Contingent Value Rights [Member] Celgene Contingent Value Rights [Member] EX-101.PRE 6 bmy-20201003_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 image00002.jpg begin 644 image00002.jpg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end GRAPHIC 8 image00003.jpg begin 644 image00003.jpg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brhc10015771_8k_htm.xml IDEA: XBRL DOCUMENT 0000014272 2020-10-03 2020-10-03 0000014272 us-gaap:CommonStockMember 2020-10-03 2020-10-03 0000014272 bmy:One000NotesDue2025Member 2020-10-03 2020-10-03 0000014272 bmy:One750NotesDue2035Member 2020-10-03 2020-10-03 0000014272 bmy:BristolMyersSquibbContingentValueRightsMember 2020-10-03 2020-10-03 0000014272 bmy:CelgeneContingentValueRightsMember 2020-10-03 2020-10-03 false 0000014272 8-K 2020-10-03 BRISTOL-MYERS SQUIBB COMPANY DE 001-01136 22-0790350 430 East 29th Street 14th Floor New York NY 10016 212 546-4000 false false true false Common Stock, $0.10 Par Value BMY NYSE 1.000% Notes due 2025 BMY25 NYSE 1.750% Notes due 2035 BMY35 NYSE Bristol-Myers Squibb Contingent Value Rights BMY RT NYSE Celgene Contingent Value Rights CELG RT NYSE false XML 10 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Oct. 03, 2020
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 03, 2020
Entity Registrant Name BRISTOL-MYERS SQUIBB COMPANY
Entity Incorporation, State or Country Code DE
Entity File Number 001-01136
Entity Tax Identification Number 22-0790350
Entity Address, Address Line One 430 East 29th Street
Entity Address, Address Line Two 14th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10016
City Area Code 212
Local Phone Number 546-4000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer true
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000014272
Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common Stock, $0.10 Par Value
Trading Symbol BMY
Security Exchange Name NYSE
1.000% Notes due 2025 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.000% Notes due 2025
Trading Symbol BMY25
Security Exchange Name NYSE
1.750% Notes due 2035 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.750% Notes due 2035
Trading Symbol BMY35
Security Exchange Name NYSE
Bristol-Myers Squibb Contingent Value Rights [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Bristol-Myers Squibb Contingent Value Rights
Trading Symbol BMY RT
Security Exchange Name NYSE
Celgene Contingent Value Rights [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Celgene Contingent Value Rights
Trading Symbol CELG RT
Security Exchange Name NYSE
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 6 95 1 false 5 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://bms.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10015771_8k.htm bmy-20201003.xsd bmy-20201003_def.xml bmy-20201003_lab.xml bmy-20201003_pre.xml brhc10015771_ex99-1.htm http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10015771_8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 6, "dts": { "definitionLink": { "local": [ "bmy-20201003_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "brhc10015771_8k.htm" ] }, "labelLink": { "local": [ "bmy-20201003_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "bmy-20201003_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "bmy-20201003.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 38, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 4, "memberStandard": 1, "nsprefix": "bmy", "nsuri": "http://bms.com/20201003", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10015771_8k.htm", "contextRef": "c20201003to20201003", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://bms.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10015771_8k.htm", "contextRef": "c20201003to20201003", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 5, "tag": { "bmy_BristolMyersSquibbContingentValueRightsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Bristol-Myers Squibb Contingent Value Rights [Member]" } } }, "localname": "BristolMyersSquibbContingentValueRightsMember", "nsuri": "http://bms.com/20201003", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "bmy_CelgeneContingentValueRightsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Celgene Contingent Value Rights [Member]" } } }, "localname": "CelgeneContingentValueRightsMember", "nsuri": "http://bms.com/20201003", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "bmy_One000NotesDue2025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "1.000% Notes due 2025 [Member]" } } }, "localname": "One000NotesDue2025Member", "nsuri": "http://bms.com/20201003", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "bmy_One750NotesDue2035Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "1.750% Notes due 2035 [Member]" } } }, "localname": "One750NotesDue2035Member", "nsuri": "http://bms.com/20201003", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001140361-20-022423-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-20-022423-xbrl.zip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end